When was Juvenescence founded?

Juvenescence was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Juvenescence located?

Juvenescence is headquartered in Dublin, Ireland. It is registered at 41 King Sreet, Liverpool, United Kingdom, L19 8EE.

Who is the current CEO of Juvenescence?

Greg Bailey of Juvenescence. They have also founded 1 company.

How many employees does Juvenescence have?

As of Mar 31, 2026, the latest employee count at Juvenescence is 42.

Is Juvenescence a funded company?

Juvenescence is a funded company, having raised a total of $290M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 06, 2017.

How much is Juvenescence worth?

The latest valuation of Juvenescence is $***** as of May 09, 2022.

When was the latest funding round of Juvenescence?

Juvenescence's latest funding was a $***** Series B round on May 07, 2025, with participation from 1 investor.

Where does Juvenescence rank among its competitors?

Juvenescence ranks 39th amongst 3649 active competitors, of which 1250 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Juvenescence, which secured $76M in May, 2025.

Who are the top competitors of Juvenescence?

Juvenescence's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Juvenescence secured the most recent funding round in May, 2025.

Juvenescence - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health. The company offers keto-diet-based exogenous ketone which helps in metabolic switches and provides anti-aging properties and protection from other age-related diseases like neurodegenerative diseases, immunosenescence & cell damage. The product is C6 Ketone Di-Ester which can raise the levels of ketones in the blood to generate ketosis.

Website: juvlabs.com
Social
Registered Address: 41 King Sreet, Liverpool, United Kingdom, L19 8EE

Key Metrics

Founded Year

2017

Location

Dublin, Ireland

Stage

Series B

Total Funding

$290M in 7 rounds

Latest Funding Round

Series B, May 07, 2025, $*****

Post Money Valuation

$***** as on May 09, 2022

Investors

Foresite Capital & 10 more

Ranked

39^th among 3649 active competitors

Employee Count

42 as on Mar 31, 2026

Investment & Acquisitions

Ro5 & 8 more

Similar Companies

Jazz Pharmaceuticals & 3526 more

View Juvenescence's full profile

Juvenescence is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Juvenescence Limited CIN: 10081257 , United Kingdom, Active	Mar 22, 2016	-	-
JUVENESCENCE US CORP. CIN: 83-1728509 , United States, Active	Aug 14, 2018	-	21 (As on Dec 31, 2021)	-

Juvenescence has raised a total funding of $290M over 7 rounds. Its first funding round was on Dec 06, 2017. Its latest funding round was a Series B round on May 07, 2025 for $*****. 1 investor participated in its latest round. Juvenescence has 9 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Juvenescence:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 07, 2025	8614325	Series B	9609955	9341367	6722131	7992760
Sep 30, 2019	6999219	Series B	5718573	9993321	5889737	2978507
Aug 19, 2019	6736085	Series B	4631038	7282439	Grok Ventures & 1 more	1197408

Access funding benchmarks and valuations. Sign up today!

View details of Juvenescence's funding rounds and investors

The founders of Juvenescence are Jim Mellon and Greg Bailey. Greg Bailey is the CEO of Juvenescence.

Here are the details of Juvenescence's key team members:

Jim Mellon: Co-Founder of Juvenescence and founder of 4 other companies, including Agronomics, Burnbrae Group and Dev Academy. They are also an angel investor in 11 startups.
Contact Info: 3 email addresses
Greg Bailey: Co-Founder & CEO of Juvenescence and founder of 2 other companies, Dev Academy and Juvenescence.
Contact Info: 1 email address

View details of Juvenescence's Founder profiles and Board Members

Juvenescence's employee count trend

Juvenescence has 42 employees as of Mar 26. Here is Juvenescence's employee count trend over the years:

Uncover Juvenescence's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Juvenescence include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Juvenescence, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Kaccelerator, BB Biotech & 7 others	72/100
9th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
39th	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Foresite Capital, IDO Investments & 9 others	68/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Juvenescence's competitors? Click here to see the top ones

Juvenescence has made 8 investments in companies including LyGenesis and Morphoceuticals. Juvenescence has also acquired 1 companies including Ro5.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 2025	Acquisition	Ro5	2018	London (United Kingdom)
Oct 05, 2023	Investments	LyGenesis	2017	Pittsburgh (United States)
Jan 23, 2023	Investments	Morphoceuticals	2020	Marblehead (United States)